| 3.06 -0.04 (-1.29%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.74 | 1-year : | 5.52 |
| Resists | First : | 4.06 | Second : | 4.73 |
| Pivot price | 3.44  |
|||
| Supports | First : | 2.99 | Second : | 2.48 |
| MAs | MA(5) : | 3.13 |
MA(20) : | 3.57 |
| MA(100) : | 4.15 |
MA(250) : | 4.03 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 6.4 |
D(3) : | 5.7 |
| RSI | RSI(14): 28.7 |
|||
| 52-week | High : | 6.75 | Low : | 2.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NRBO ] has closed above bottom band by 14.7%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.17 - 3.19 | 3.19 - 3.2 |
| Low: | 2.98 - 3 | 3 - 3.02 |
| Close: | 3.02 - 3.06 | 3.06 - 3.09 |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Thu, 29 Feb 2024
NeuroBo stock jumps 14% on weight-loss drug update (NASDAQ:NRBO) - Seeking Alpha
Tue, 06 Feb 2024
Does Neurobo Pharmaceuticals Inc (NRBO) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver
Thu, 01 Feb 2024
Healthcare Stocks Moving Up and Down Thursday: NRBO, BRTX, AHG, CMND, REVB, CMAX, TCRT, VVOS - InvestorsObserver
Thu, 01 Feb 2024
FDA clears NeuroBo's obesity drug for Phase 1 trials - Investing.com Canada
Thu, 01 Feb 2024
Do Traders Think Neurobo Pharmaceuticals Inc (NRBO) Can Keep Climbing Thursday? - InvestorsObserver
Tue, 27 Jun 2023
NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 61.6 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 62 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -2.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.3 % |
| Return on Equity (ttm) | -64.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -1.25 |
| PEG Ratio | 0 |
| Price to Book value | 0.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|